Primary melanoma stage as a predictor of survival in advanced disease: Findings from the Spanish Melanoma Registry GEM1801
Authors:
- Maria Gonzalez-CaoMGMaria Gonzalez-Cao
- Susana PuigSPSusana Puig
- José Luis ManzanoJMJosé Luis Manzano
- Miguel-Ángel Berciano-GuerreroMBMiguel-Ángel Berciano-Guerrero
- Ainara SoriaASAinara Soria
- Lourdes Gutiérrez SanzLSLourdes Gutiérrez Sanz
- Pablo Cerezuela-FuentesPCPablo Cerezuela-Fuentes
- Guillermo CrespoGCGuillermo Crespo
- Eva Muñoz-CouseloEMEva Muñoz-Couselo
- Teresa PuértolasTPTeresa Puértolas
- Carlos Aguado de la RosaCRCarlos Aguado de la Rosa
- Luis Antonio FernándezLFLuis Antonio Fernández
- 5 October 2026
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2025
- Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant TreatmentJournal of Clinical Oncology, 2022
- Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease RecurrenceActa Dermato-Venereologica, 2021
- Impact of initial stage on metastatic melanoma survivalMelanoma Research, 2019
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)The Lancet, 2017
- Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous MelanomaAnnals of Surgical Oncology, 2012
- Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanomaJournal of Clinical Investigation, 2010
- Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma GroupThe Journal of Pathology, 2002